CANSINOBIO (06185) has released its 2025 performance report, showing an operating revenue of 1.068 billion yuan, a year-on-year increase of 26.18%. Net profit attributable to owners of the parent company was 27.8727 million yuan, marking a turnaround from a loss to a profit compared to the previous year. Basic earnings per share were 0.11 yuan. During the reporting period, the group continued to implement its development strategy focused on innovation and commercialization. MENHUA®, China's first quadrivalent meningococcal conjugate vaccine, maintained sustained growth. Concurrently, the group advanced cost reduction and efficiency enhancement initiatives, effectively controlling various expenses. The coordination between production and sales was further optimized, leading to an improvement in the gross profit margin. The group's overall profitability improved significantly, successfully achieving a positive net profit attributable to the parent company for the period. With the rapid progress of the group's R&D projects and the development of international collaborations, it also received government special subsidies and international specialized R&D funding support, and recognized related non-recurring gains during the reporting period. During the reporting period, operating profit, total profit, and net profit attributable to owners of the parent company all turned from loss to profit year-on-year. Basic earnings per share and weighted average return on equity turned from negative to positive. The net loss attributable to owners of the parent company after deducting non-recurring gains and losses narrowed year-on-year. These changes were primarily due to a 26.18% year-on-year increase in operating revenue, the group's continuous optimization of resource allocation, implementation of cost-cutting and efficiency measures leading to sustained operational efficiency improvements, savings achieved in various expenses during the period, and the realization of gains related to government subsidies and international R&D funding. Consequently, several key financial data points and indicators related to profitability achieved positive year-on-year growth in the reporting period. At the end of the reporting period, the company's share capital was approximately 247 million shares, a decrease of approximately 410,000 shares compared to the beginning of the period, mainly due to the cancellation of some A-shares repurchased in previous years.